Literature DB >> 3966924

Inhibition by dihydropyridine class calcium channel blockers of tumor cell-platelet-endothelial cell interactions in vitro and metastasis in vivo.

K V Honn, J M Onoda, K Pampalona, M Battaglia, G Neagos, J D Taylor, C A Diglio, B F Sloane.   

Abstract

Three calcium channel blockers of the dihydropyridine class were tested in vitro for their effects on tumor cell-platelet-endothelial cell interactions and in vivo for antimetastatic properties. Felodipine, nimodipine and nifedipine inhibited tumor cell-induced platelet aggregation in vitro in a dose-dependent manner. These compounds also inhibited platelet-enhanced tumor cell adhesion to endothelial cells in vitro. Lung colony formation ("experimental" metastasis) and spontaneous pulmonary metastasis were inhibited by felodipine, nimodipine and nifedipine. From the present studies on three calcium channel blockers of the dihydropyridine class we hypothesize that calcium channel blockers may represent a new generic class of antimetastatic agents.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3966924     DOI： 10.1016/0006-2952(85)90130-3

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN： 0006-2952            Impact factor:   5.858


  17 in total

Review 1.  Interactions between cancer cells and the microvasculature: a rate-regulator for metastasis.

Authors:  L Weiss; F W Orr; K V Honn
Journal:  Clin Exp Metastasis       Date:  1989 Mar-Apr       Impact factor: 5.150

Review 2.  Motivation for Launching a Cancer Metastasis Inhibition (CMI) Program.

Authors:  Jill M Pulley; Rebecca N Jerome; Martin L Ogletree; Gordon R Bernard; Robert R Lavieri; Nicole M Zaleski; Charles C Hong; Jana K Shirey-Rice; Carlos L Arteaga; Ingrid A Mayer; Kenneth J Holroyd; Rebecca S Cook
Journal:  Target Oncol       Date:  2018-02       Impact factor: 4.493

Review 3.  Felodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension.

Authors:  E Saltiel; A G Ellrodt; J P Monk; M S Langley
Journal:  Drugs       Date:  1988-10       Impact factor: 9.546

4.  Inhibition of phospholipase A2 (PLA2) activity by nifedipine and nisoldipine is independent of their calcium-channel-blocking activity.

Authors:  J Chang; E Blazek; R P Carlson
Journal:  Inflammation       Date:  1987-09       Impact factor: 4.092

5.  Vessel invasion by tumour cells. An ultrastructural study.

Authors:  P Constantinides; D Hewitt; M Harkey
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1989

Review 6.  Shaping future strategies for the pharmacological control of tumor cell metastases.

Authors:  R G Greig; D L Trainer
Journal:  Cancer Metastasis Rev       Date:  1986       Impact factor: 9.264

7.  Tobacco smoke tumor promoters, catechol and hydroquinone, induce oxidative regulation of protein kinase C and influence invasion and metastasis of lung carcinoma cells.

Authors:  R Gopalakrishna; Z H Chen; U Gundimeda
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-06       Impact factor: 11.205

8.  Combination chemotherapy with cisplatin and nifedipine: synergistic antitumor effects against a cisplatin-resistant subline of the B16 amelanotic melanoma.

Authors:  J M Onoda; K K Nelson; S M Pilarski; N S White; R G Mihu; K V Honn
Journal:  Clin Exp Metastasis       Date:  1990 Jan-Feb       Impact factor: 5.150

9.  Inhibition of tumor invasion and metastasis by calcium spirulan (Ca-SP), a novel sulfated polysaccharide derived from a blue-green alga, Spirulina platensis.

Authors:  T Mishima; J Murata; M Toyoshima; H Fujii; M Nakajima; T Hayashi; T Kato; I Saiki
Journal:  Clin Exp Metastasis       Date:  1998-08       Impact factor: 5.150

10.  Calcium channel blocker treatment of tumor cells induces alterations in the cytoskeleton, mobility of the integrin alpha IIb beta 3 and tumor-cell-induced platelet aggregation.

Authors:  J Timar; H Chopra; X Rong; J S Hatfield; S E Fligiel; J M Onoda; J D Taylor; K V Honn
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.